These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
103 related articles for article (PubMed ID: 8305624)
21. Diagnosis of primary liver cancer using lectin affinity chromatography of serum alkaline phosphatase. Lu Y; Lu Q; Chen HL J Exp Clin Cancer Res; 1997 Mar; 16(1):75-80. PubMed ID: 9148865 [TBL] [Abstract][Full Text] [Related]
22. [Clinical significance of vascular endothelial growth factor in sera of patients with gynaecological malignant tumors]. Peng XP; Li JD; Li MD; Ye XM; Yan WC Ai Zheng; 2002 Feb; 21(2):181-5. PubMed ID: 12479072 [TBL] [Abstract][Full Text] [Related]
23. Serum deoxyribonuclease I activity can be used as a sensitive marker for detection of transient myocardial ischaemia induced by percutaneous coronary intervention. Arakawa K; Kawai Y; Kumamoto T; Morikawa N; Yoshida M; Tada H; Kawaguchi R; Taniguchi K; Miyamori I; Kominato Y; Kishi K; Yasuda T Eur Heart J; 2005 Nov; 26(22):2375-80. PubMed ID: 15821005 [TBL] [Abstract][Full Text] [Related]
24. Diagnostic potential of circulating nucleic acids for oncology. Goessl C Expert Rev Mol Diagn; 2003 Jul; 3(4):431-42. PubMed ID: 12877383 [TBL] [Abstract][Full Text] [Related]
25. [Tumor markers--serologic parameters for monitoring and therapeutic control of cancer patients]. Birkmayer J Wien Med Wochenschr; 1988 Jun; 138(11-12):276-8. PubMed ID: 3176507 [TBL] [Abstract][Full Text] [Related]
26. Detection and characterization of circulating microsatellite-DNA in blood of patients with breast cancer. Schwarzenbach H; Müller V; Stahmann N; Pantel K Ann N Y Acad Sci; 2004 Jun; 1022():25-32. PubMed ID: 15251935 [TBL] [Abstract][Full Text] [Related]
27. Testing for anti-p53 antibodies increases the diagnostic sensitivity of conventional tumor markers. Müller M; Meyer M; Schilling T; Ulsperger E; Lehnert T; Zentgraf H; Stremmel W; Volkmann M; Galle PR Int J Oncol; 2006 Oct; 29(4):973-80. PubMed ID: 16964393 [TBL] [Abstract][Full Text] [Related]
28. Serum tumor markers in patients with breast cancer. Lumachi F; Basso SM Expert Rev Anticancer Ther; 2004 Oct; 4(5):921-31. PubMed ID: 15485325 [TBL] [Abstract][Full Text] [Related]
29. Immunochemical assay for deoxyribonuclease activity in body fluids. Cherepanova A; Tamkovich S; Pyshnyi D; Kharkova M; Vlassov V; Laktionov P J Immunol Methods; 2007 Aug; 325(1-2):96-103. PubMed ID: 17618645 [TBL] [Abstract][Full Text] [Related]
30. [Measurement of serum tissue polypeptide antigen (TPA) in patients with malignant tumor using prolifigen TPA-M "Daiichi" kit]. Sakahara H; Endo K; Torizuka K; Itoh K; Ohuchi N; Inaba N; Miyaji Y; Takayama M; Ishii K; Takagi H; Konishi J; Fukuoka M; Fukuchi M; Ohkawa J; Kagawa S; Kondo S; Shirouzu K; Iguchi H Gan To Kagaku Ryoho; 1996 May; 23(6):733-43. PubMed ID: 8645025 [TBL] [Abstract][Full Text] [Related]
31. [Zymography--method for quantitation of activity on gelatinase A (pro-MMP-2, 72 kDa) and gelatinase B (pro-MMP-9, 92 kDa) in serum of patients with breast cancer]. Sliwowska I; Kopczyński Z Wiad Lek; 2007; 60(5-6):241-7. PubMed ID: 17966888 [TBL] [Abstract][Full Text] [Related]
32. Clinical usefulness of serum antip53 antibodies for prostate cancer detection: a comparative study with prostate specific antigen parameters. Suzuki H; Akakura K; Igarashi T; Ueda T; Ito H; Watanabe M; Nomura F; Ochiai T; Shimada H J Urol; 2004 Jan; 171(1):182-6. PubMed ID: 14665872 [TBL] [Abstract][Full Text] [Related]
34. Serum S-100 protein: a potentially useful prognostic marker in cutaneous melanoma. Abraha HD; Fuller LC; Du Vivier AW; Higgins EM; Sherwood RA Br J Dermatol; 1997 Sep; 137(3):381-5. PubMed ID: 9349333 [TBL] [Abstract][Full Text] [Related]
35. Serum selenium in head and neck cancer patients--a new marker of tumor activity? Büntzel J; Micke O; Glatzel M; Fröhlich D; Bruns F; Mücke R; Schönekaes KG Anticancer Res; 2005; 25(3A):1711-2. PubMed ID: 16033088 [TBL] [Abstract][Full Text] [Related]
36. [Detection of serum p53 antibodies in colorectal cancer patients and the clinical significance of postoperative monitoring]. Takeda A; Shimada H; Nakajima K; Imaseki H; Okazumi S; Takayama W; Hayashi H; Iwasaki K; Sasagawa S; Chou A; Natsume T; Kouno T; Kondou S; Maeda T; Hori S; Suzuki T; Ochiai T; Isono K Gan To Kagaku Ryoho; 1999 Dec; 26(14):2189-94. PubMed ID: 10635303 [TBL] [Abstract][Full Text] [Related]
37. Circulating cathepsin K and cystatin C in patients with cancer related bone disease: clinical and therapeutic implications. Tumminello FM; Flandina C; Crescimanno M; Leto G Biomed Pharmacother; 2008 Feb; 62(2):130-5. PubMed ID: 17728092 [TBL] [Abstract][Full Text] [Related]
38. A radial diffusion assay for plasma and serum deoxyribonuclease I. Chitrabamrung S; Bannett JS; Rubin RL; Tan EM Rheumatol Int; 1981; 1(2):49-53. PubMed ID: 6287559 [TBL] [Abstract][Full Text] [Related]
39. Clinical investigation of serum deoxyribonuclease: I. Analysis of serum deoxyribonuclease activity in comparison with normal and after endoscopic retrograde pancreatography. Funakoshi A; Kimura T; Wakasugi H; Ibayashi H Gastroenterol Jpn; 1979 Oct; 14(5):432-5. PubMed ID: 42597 [TBL] [Abstract][Full Text] [Related]
40. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. Brown JE; Cook RJ; Major P; Lipton A; Saad F; Smith M; Lee KA; Zheng M; Hei YJ; Coleman RE J Natl Cancer Inst; 2005 Jan; 97(1):59-69. PubMed ID: 15632381 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]